Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158743 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Digibind for Treatment of Severe Preeclampsia
A Phase 2 study, sponsored by BTG International.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00158743 is a Phase 2 study that has completed, run by BTG International. The registered enrollment target is 51 participants.
The verdict
NCT00158743, a Phase 2 study, has completed, sponsored by BTG International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a commercially available anti-digoxin antibody, Digibind, can delay delivery in patients with severe pre-eclampsia. If so, this would allow more time for maternally administered steroids to prevent the development of respiratory complications in premature infants.
Interventions
- DRUG Anti-digoxin antibody (FAB fragment)
- OTHER sodium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00158743
The ClinicalTrials.gov registry entry for NCT00158743 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BTG International, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anti-digoxin antibody (FAB fragment) is the first listed.
NCT00158743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00158743 about?
NCT00158743 is a clinical study titled "Efficacy Study of Digibind for Treatment of Severe Preeclampsia". The purpose of this study is to determine whether a commercially available anti-digoxin antibody, Digibind, can delay delivery in patients with severe pre-eclampsia. If so, this would allow more time for maternally administered steroids to prevent the development of respiratory complications in prem...
What is the current status of trial NCT00158743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2004-02. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00158743?
The interventions under investigation include: Anti-digoxin antibody (FAB fragment) (DRUG), sodium chloride (OTHER).
Who is sponsoring clinical trial NCT00158743?
This trial is sponsored by BTG International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.